IDYA

In the past six months, IDEAYA Biosciences' stock (IDYA) experienced several notable events. In April 2026, the company announced positive topline results from the Phase 2/3 registrational trial of darovasertib, which met its primary endpoint and led to the initiation of an NDA submission. On August 4, 2026, IDEAYA reported its second-quarter financial results, missing EPS estimates but exceeding revenue expectations with an 8800.0% year-over-year increase to $8.86 million, and reported approximately $1.24 billion in cash with runway guidance into 2030. In August 2026, IDEAYA announced a successful FDA Type C meeting, finalizing the design of a Phase 3 registrational trial for IDE849, targeting initiation by year-end 2026. On October 6, 2026, CEO Yujiro S. Hata sold 26,338 shares of common stock for approximately $985,396 under a Rule 10b5-1 trading plan. Overall, IDYA's stock has trended up by 16.47% in the past six months and 34.4% over the past year, although the 30-day share price return was down 4.71%.